GlycoMimetics, Inc. (NASDAQ: GLYC) announced today that Chief Executive Officer Rachel King will present in November at two investor conferences, as follows:

• The Stifel 2015 Healthcare Conference at The New York Palace Hotel in New York, New York on November 17, 2015, from 11:00 a.m. to 11:45 a.m. EST.
• The Jefferies Autumn 2015 Global Healthcare Conference at The May Fair Hotel, Stratton Street, London on November 19, 2015, from 3:20 p.m. to 4:00 p.m. BST.

To access the live webcasts and subsequent archived recordings for the presentations, please visit the GlycoMimetics website at www.glycomimetics.com.

About GlycoMimetics, Inc.

GlycoMimetics is a clinical stage biotechnology company focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. GlycoMimetics entered into an exclusive license agreement with Pfizer for rivipansel in October 2011. Under the license agreement, Pfizer is responsible for the clinical development, regulatory approval and potential commercialization of rivipansel. A GlycoMimetics wholly-owned candidate therapy (GMI-1271) for acute myeloid leukemia (AML) and other blood disorders is also in clinical trials. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using its expertise in carbohydrate chemistry and knowledge of carbohydrate biology, GlycoMimetics is developing a pipeline of glycomimetic drug candidates that inhibit disease-related functions of carbohydrates, such as the roles they play in inflammation, cancer and infection. Learn more at www.glycomimetics.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20151112006510/en/